Liraglutide FAQ: common questions answered

A daily GLP-1 injection approved for weight management and type 2 diabetes.

Also called: Saxenda, Victoza, NN2211, Xultophy component.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

  • Is Liraglutide FDA-approved? Yes: Victoza (type 2 diabetes age 10+; fewer major cardiovascular events in adults with diabetes and established cardiovascular disease.); Saxenda (long-term weight management in adults and eligible adolescents age 12+, with diet and activity.); Xultophy 100/3.6 (fixed insulin degludec/liraglutide combination for adult type 2 diabetes.). Saxenda removed its suicidal-thoughts warning in February 2026 after FDA found no increased risk. A generic product’s indications may differ.
  • How do people take it? Under the skin, once daily. Source: drug label.
  • Can I take it with Metformin? Studied add-on for glucose control; lower liraglutide doses were tested in LEAD-2. Both can cause stomach symptoms; metformin has its own kidney restrictions. Source: studied in a trial. Ask a doctor before combining anything.
  • Is it banned in sport? No, it is not on the banned list (WADA 2026). Liraglutide alone is permitted. Xultophy contains insulin, prohibited at all times; athletes need a therapeutic use exemption, supported by specialist records of diagnosis and insulin need.
  • How do I store it once opened? Saxenda/Victoza after first use: 30 days at 2–8°C or 15–30°C. Xultophy after first use: 21 days at 2–8°C or 15–30°C.

Related to Liraglutide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.